Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
06 May 2025 | Story Tshepo Tsotetsi | Photo Supplied
Critical Dialogue
Guest speaker, Prof Gordon Zide, delivers his keynote address at the EDSA Critical Dialogue Series 2025.

The Office of the Executive Director: Student Affairs at the University of the Free State (UFS) hosted its annual Critical Dialogue Series on 29 April 2025 at the Centenary Complex on the Bloemfontein Campus. The dialogue brought together students, staff, and university leadership for an engaging conversation around ethical and servant leadership in higher education.

 

A conversation rooted in purpose

In his opening address, Temba Hlasho, Executive Director for Student Affairs said the dialogue was designed to provoke honest reflection and engagement on issues that affect student experience and institutional culture.

“We believe that there has to be some sort of transparency in terms of having to talk about topical issues that are very critical, that also touch on the very nerve of student experience,” Hlasho said.

He encouraged student leaders to see the platform not as ceremonial, but as a call to action. “You are in a country today where ethics have almost decayed. You, as the future of this country, will rely solely on the young people to change the narrative.”

 

Leadership anchored in service

UFS Vice-Chancellor and Principal Prof Hester C. Klopper delivered a powerful message on the importance of ethical and servant leadership in guiding the university’s direction. “Leadership – and specifically ethical and servant leadership – forms the cornerstone of what we stand for at the University of the Free State.”

She spoke about accountability, fairness, and leading with integrity. “It means treating every student fairly regardless of background or belief, and holding yourself accountable for your actions and decisions.”

Prof Klopper also highlighted the vital role student leaders play in shaping a culture of trust and excellence. “Leadership is not a title or a position, but a daily choice to serve with integrity, empathy, and purpose.”

 

Ubuntu, transformation, and power dynamics

The event’s keynote speaker was Prof Gordon Zide, an accomplished scholar, academic, intellectual, Africanist, author, transformation specialist, motivational speaker, and a former Vice-Chancellor and Principal of the Vaal University of Technology. Prof Zide is also a former Registrar at the University of South Africa. Drawing from a lifetime of experience in the sector, he interrogated the moral responsibilities of leadership within the South African higher education landscape.

“Leadership is a function of being a servant and being in charge of others,” he said. “It also requires the capacity to give strategic direction for the effective, efficient, and valued functioning of organisations.”

He emphasised that ethical leadership should be grounded in values such as vision, passion, patience, integrity, honesty, decisiveness, character, and charisma. Reflecting on the African philosophy of ubuntu, Prof Zide remarked: “When talking about servant leadership, it’s important to recognise other people and say to yourself: ‘I am what I am because of other people.’”

He encouraged students, particularly the current generation, to take charge and assume ethical leadership roles in their spaces. Referencing prominent anti-apartheid figure Robert Sobukwe, he urged, “Even when we are no longer here, they will always remember that we were there.”

Prof Zide also noted the practical benefits of ethical leadership in institutions, saying that it improves brand image, boosts morale among staff and students, and strengthens the recruitment process. He concluded by challenging the Department of Higher Education and Training (DHET), saying its tendency to micromanage universities undermines the autonomy and leadership authority of institutional management.

 

A call to lead with intention

Reflecting on the impact of the event, Acting President of the Institutional Student Representative Council (ISRC) Mpho Maloka said, “These kinds of conversations are needed because they help us go back to the ‘why’ – why we became student leaders in the first place, and how we can serve students in ways that actually make a difference.”

She added, “People have turned student leadership into something so political that others don’t even want to get involved. Dialogues like this bring it back to what really matters – serving students and growing as ethical leaders.”

As Prof Klopper concluded: “The lessons in ethical and servant leadership that you learn and practise here prepare you not just for impactful careers, but for responsible citizenship in a world desperately in need of ethical leadership.”

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept